US20050152846A1 - Formoterol superfine formulation - Google Patents

Formoterol superfine formulation Download PDF

Info

Publication number
US20050152846A1
US20050152846A1 US10/504,151 US50415105A US2005152846A1 US 20050152846 A1 US20050152846 A1 US 20050152846A1 US 50415105 A US50415105 A US 50415105A US 2005152846 A1 US2005152846 A1 US 2005152846A1
Authority
US
United States
Prior art keywords
pharmaceutical formulation
formulation according
formulation
hfa
formoterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/504,151
Other languages
English (en)
Inventor
Rebecca Davies
David Ganderton
David Lewis
Brian Meakin
Tanya Church
Gaetano Brambilla
Alessandra Ferraris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27790093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050152846(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP02004786A external-priority patent/EP1340492A1/en
Priority claimed from EP02023589A external-priority patent/EP1415647A1/en
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Assigned to CHIESI FARMACEUTICI S.P.A. reassignment CHIESI FARMACEUTICI S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRAMBILLA, GAETANO, CHURCH, TANYA KATHLEEN, DAVIES, REBECCA JAINE, FERRARIS, ALESSANDRA, GANDERTON, DAVID, LEWIS, DAVID ANDREW, MEAKIN, BRIAN JOHN
Publication of US20050152846A1 publication Critical patent/US20050152846A1/en
Priority to US12/873,690 priority Critical patent/US8313732B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
US10/504,151 2002-03-01 2003-02-26 Formoterol superfine formulation Abandoned US20050152846A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/873,690 US8313732B2 (en) 2002-03-01 2010-09-01 Formoterol superfine formulation

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02004786A EP1340492A1 (en) 2002-03-01 2002-03-01 Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP02004786.6 2002-03-01
EP02023589.1 2002-10-23
EP02023589A EP1415647A1 (en) 2002-10-23 2002-10-23 "Long-acting beta-2 agonists ultrafine formulations"
PCT/EP2003/001964 WO2003074024A1 (en) 2002-03-01 2003-02-26 Formoterol superfine formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001964 A-371-Of-International WO2003074024A1 (en) 2002-03-01 2003-02-26 Formoterol superfine formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/873,690 Continuation US8313732B2 (en) 2002-03-01 2010-09-01 Formoterol superfine formulation

Publications (1)

Publication Number Publication Date
US20050152846A1 true US20050152846A1 (en) 2005-07-14

Family

ID=27790093

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/504,151 Abandoned US20050152846A1 (en) 2002-03-01 2003-02-26 Formoterol superfine formulation
US10/505,861 Abandoned US20050154013A1 (en) 2002-03-01 2003-02-27 Pressurised metered dose inhalers containing solutions of beta-2 agonists
US12/487,988 Abandoned US20090263488A1 (en) 2002-03-01 2009-06-19 Pressurised metered dose inhalers containing solutions of beta-2 agonists
US12/873,690 Expired - Lifetime US8313732B2 (en) 2002-03-01 2010-09-01 Formoterol superfine formulation

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/505,861 Abandoned US20050154013A1 (en) 2002-03-01 2003-02-27 Pressurised metered dose inhalers containing solutions of beta-2 agonists
US12/487,988 Abandoned US20090263488A1 (en) 2002-03-01 2009-06-19 Pressurised metered dose inhalers containing solutions of beta-2 agonists
US12/873,690 Expired - Lifetime US8313732B2 (en) 2002-03-01 2010-09-01 Formoterol superfine formulation

Country Status (36)

Country Link
US (4) US20050152846A1 (US20050154013A1-20050714-C00001.png)
EP (6) EP3494995B1 (US20050154013A1-20050714-C00001.png)
JP (3) JP2005523905A (US20050154013A1-20050714-C00001.png)
KR (2) KR100947409B1 (US20050154013A1-20050714-C00001.png)
CN (2) CN100398094C (US20050154013A1-20050714-C00001.png)
AR (2) AR038641A1 (US20050154013A1-20050714-C00001.png)
AT (1) ATE465712T1 (US20050154013A1-20050714-C00001.png)
AU (2) AU2003222753B2 (US20050154013A1-20050714-C00001.png)
BR (2) BRPI0308274B8 (US20050154013A1-20050714-C00001.png)
CA (2) CA2477881C (US20050154013A1-20050714-C00001.png)
CO (2) CO5611092A2 (US20050154013A1-20050714-C00001.png)
CY (4) CY1111133T1 (US20050154013A1-20050714-C00001.png)
DE (1) DE60332321D1 (US20050154013A1-20050714-C00001.png)
DK (4) DK3494995T3 (US20050154013A1-20050714-C00001.png)
EA (2) EA007735B1 (US20050154013A1-20050714-C00001.png)
ES (4) ES2780127T3 (US20050154013A1-20050714-C00001.png)
GE (2) GEP20063986B (US20050154013A1-20050714-C00001.png)
HK (1) HK1079425A1 (US20050154013A1-20050714-C00001.png)
HR (2) HRP20040753A2 (US20050154013A1-20050714-C00001.png)
HU (3) HUE044926T2 (US20050154013A1-20050714-C00001.png)
IL (3) IL163843A0 (US20050154013A1-20050714-C00001.png)
LT (3) LT3536344T (US20050154013A1-20050714-C00001.png)
MA (1) MA27175A1 (US20050154013A1-20050714-C00001.png)
ME (3) ME00077B (US20050154013A1-20050714-C00001.png)
MX (2) MXPA04008372A (US20050154013A1-20050714-C00001.png)
MY (2) MY143517A (US20050154013A1-20050714-C00001.png)
NO (2) NO342575B1 (US20050154013A1-20050714-C00001.png)
NZ (2) NZ535018A (US20050154013A1-20050714-C00001.png)
PE (2) PE20030824A1 (US20050154013A1-20050714-C00001.png)
PL (2) PL209212B1 (US20050154013A1-20050714-C00001.png)
PT (4) PT1480615E (US20050154013A1-20050714-C00001.png)
RS (2) RS52387B (US20050154013A1-20050714-C00001.png)
SI (4) SI1480615T1 (US20050154013A1-20050714-C00001.png)
TN (2) TNSN04147A1 (US20050154013A1-20050714-C00001.png)
TW (2) TWI347197B (US20050154013A1-20050714-C00001.png)
WO (2) WO2003074024A1 (US20050154013A1-20050714-C00001.png)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030089369A1 (en) * 1998-11-25 2003-05-15 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20030190287A1 (en) * 1997-06-13 2003-10-09 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US20030190289A1 (en) * 2000-05-12 2003-10-09 David Lewis Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US20040033201A1 (en) * 1999-06-18 2004-02-19 3M Innovative Properties Company Process for making chemically stable C-17/21 OH 20-ketosteroid aerosol products
US20040101483A1 (en) * 2001-03-30 2004-05-27 Rudi Muller-Walz Medical aerosol formulations
US20040184993A1 (en) * 1998-11-25 2004-09-23 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition containing HFA 227 and HFA 134a
US20050034720A1 (en) * 2000-01-07 2005-02-17 Gaetano Brambilla Aerosol inhaler
US20050129621A1 (en) * 2002-03-01 2005-06-16 Chiesi Farmaceutici S.P.A. Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US20050154013A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers containing solutions of beta-2 agonists
US20050163722A1 (en) * 2001-07-02 2005-07-28 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US20050220718A1 (en) * 2004-02-27 2005-10-06 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20060002863A1 (en) * 2004-07-02 2006-01-05 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant
US20060083693A1 (en) * 2000-05-22 2006-04-20 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20060120966A1 (en) * 2002-10-23 2006-06-08 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US20070020190A1 (en) * 2003-02-27 2007-01-25 Roberta Razzetti Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
US20070025920A1 (en) * 2004-02-27 2007-02-01 David Lewis Stable Pharmaceutical Solution Formulations for Pressurized Metered Dose Inhalers
US20070086953A1 (en) * 2004-05-13 2007-04-19 Brian Meakin Medicinal Aerosol Formulation Products With Improved Chemical Stability
US20070218011A1 (en) * 2003-10-09 2007-09-20 Rudi Mueller-Walz Aerosol Formulation Comprising Formoterol in Suspension
US20070256685A1 (en) * 2003-10-09 2007-11-08 Rudi Mueller-Walz Aerosol Formulations Comprising Formoterol Fumarate Dihydrate
US20090092559A1 (en) * 2006-04-11 2009-04-09 Boehringer Ingelheim Pharma Gbmh Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US20150297118A1 (en) * 2012-11-15 2015-10-22 Jp Respiratory Technology Ab Device and method for pulmonary function measurement
US10471077B2 (en) 2009-10-16 2019-11-12 Jagotec Ag Medicinal aerosol formulations

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CA2534120C (en) * 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
UA88894C2 (ru) * 2004-02-27 2009-12-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Стабильные фармацевтические композиции в виде растворов для ингаляторов с дозатором, которые находятся под давлением
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP5259193B2 (ja) * 2005-02-25 2013-08-07 チエシイ・ファルマセウテイシイ・エス・ペー・アー 加圧下にある用量計量型吸入器用の金属イオン封鎖剤を含む薬用エーロゾル配合物
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
GB2461752B (en) * 2008-07-14 2013-04-17 Neo Inhalation Products Ltd Metered dose inhaler
AU2009308412B2 (en) * 2008-10-23 2015-11-26 Sunovion Pharmaceuticals Inc. Arformoterol and tiotropium compositions and methods for use
EA021917B1 (ru) 2009-12-23 2015-09-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированная терапия астмы и copd
PE20121467A1 (es) 2009-12-23 2012-11-07 Chiesi Farma Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
EP2360147A1 (en) * 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
CA2805700A1 (en) * 2010-07-16 2012-01-19 Cipla Limited Pharmaceutical compositions comprising r(+) budesonide and formoterol
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
RU2504402C1 (ru) * 2012-11-20 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный состав в форме аэрозоля для лечения бронхиальной астмы и хронической обструктивной болезни легких
CN106667973A (zh) * 2017-01-22 2017-05-17 西咸新区世云工研坊生物科技有限公司 一种用于防雾霾损伤的组合物及其制备方法和喷剂
EP4096623A1 (en) 2020-01-28 2022-12-07 Chiesi Farmaceutici S.p.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
KR20220144361A (ko) 2020-02-20 2022-10-26 키에시 파르마슈티시 엣스. 피. 에이. 완충된 약제학적 제제를 포함하는 가압 정량 흡입기
WO2023227783A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6131566A (en) * 1995-04-14 2000-10-17 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
US6150418A (en) * 1998-10-17 2000-11-21 Boehringer Ingelheim Pharma Kg Active substance concentrate with formoterol, suitable for storage
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20030066525A1 (en) * 1998-11-25 2003-04-10 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20030077230A1 (en) * 1998-06-19 2003-04-24 Blondino Frank E. Pressurized metered dose inhalers and pharmaceutical aerosol fomulations
US6589508B1 (en) * 1991-04-05 2003-07-08 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
US20030190289A1 (en) * 2000-05-12 2003-10-09 David Lewis Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US6713047B1 (en) * 1998-11-25 2004-03-30 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition containing HFA 227 and HFA 134a
US6716414B2 (en) * 2000-05-22 2004-04-06 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20050129621A1 (en) * 2002-03-01 2005-06-16 Chiesi Farmaceutici S.P.A. Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US20050154013A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers containing solutions of beta-2 agonists
US20050220718A1 (en) * 2004-02-27 2005-10-06 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US6964759B2 (en) * 2000-02-22 2005-11-15 Chiesi Farmaceutici S.P.A. Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) * 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) * 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US4584320A (en) * 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
IT1244441B (it) * 1990-09-13 1994-07-15 Chiesi Farma Spa Dispositivo per l'inalazione boccale di farmaci aerosol
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
CA2116579A1 (en) * 1991-08-29 1993-03-18 Christoph Klein Medical device for inhaling doses of spray
DE4230876A1 (de) * 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
ZA939195B (en) * 1992-12-09 1995-06-08 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
WO1994013263A1 (en) 1992-12-09 1994-06-23 Jager Paul D Stabilized medicinal aerosol solution formulations
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
US5899201A (en) * 1993-05-26 1999-05-04 Minnesota Mining And Manufacturing Company Aerosol actuator
WO1995017195A1 (en) * 1993-12-20 1995-06-29 Minnesota Mining And Manufacturing Company Flunisolide aerosol formulations
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
EE04004B1 (et) * 1995-04-14 2003-04-15 Glaxo Wellcome Inc. Flutikasoonpropionaati doseeriv inhalaator
US5637505A (en) * 1995-05-19 1997-06-10 Chiron Diagnostics Corporation Method to prepare dye-based reference material
CA2264524A1 (en) * 1996-10-04 1998-04-09 Norihiro Shinkai Patch
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6413496B1 (en) * 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
WO1998034595A1 (de) * 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6188933B1 (en) * 1997-05-12 2001-02-13 Light & Sound Design Ltd. Electronically controlled stage lighting system
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6045784A (en) * 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
ES2234266T3 (es) 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
EP1862164A3 (de) * 1998-11-13 2012-12-26 Jagotec AG Trockenpulver zur Inhalation
US6352152B1 (en) * 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6290930B1 (en) * 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
EP1143930B8 (en) * 1999-09-11 2008-03-19 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6578125B2 (en) 2000-02-14 2003-06-10 Sanyo Electric Co., Ltd. Memory access circuit and memory access control circuit
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009773D0 (en) 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
EP1241113A1 (en) 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
ATE267591T1 (de) * 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589508B1 (en) * 1991-04-05 2003-07-08 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
US6131566A (en) * 1995-04-14 2000-10-17 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
US20040062720A1 (en) * 1997-06-13 2004-04-01 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20030206870A1 (en) * 1997-06-13 2003-11-06 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US20030190287A1 (en) * 1997-06-13 2003-10-09 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US20030077230A1 (en) * 1998-06-19 2003-04-24 Blondino Frank E. Pressurized metered dose inhalers and pharmaceutical aerosol fomulations
US6150418A (en) * 1998-10-17 2000-11-21 Boehringer Ingelheim Pharma Kg Active substance concentrate with formoterol, suitable for storage
US20030066525A1 (en) * 1998-11-25 2003-04-10 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US6713047B1 (en) * 1998-11-25 2004-03-30 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition containing HFA 227 and HFA 134a
US20030089369A1 (en) * 1998-11-25 2003-05-15 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20040096399A1 (en) * 1998-11-25 2004-05-20 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20040184993A1 (en) * 1998-11-25 2004-09-23 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition containing HFA 227 and HFA 134a
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6964759B2 (en) * 2000-02-22 2005-11-15 Chiesi Farmaceutici S.P.A. Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease
US20030190289A1 (en) * 2000-05-12 2003-10-09 David Lewis Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US6716414B2 (en) * 2000-05-22 2004-04-06 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US7018618B2 (en) * 2000-05-22 2006-03-28 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20050154013A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers containing solutions of beta-2 agonists
US20050129621A1 (en) * 2002-03-01 2005-06-16 Chiesi Farmaceutici S.P.A. Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US20050220718A1 (en) * 2004-02-27 2005-10-06 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040062720A1 (en) * 1997-06-13 2004-04-01 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20030190287A1 (en) * 1997-06-13 2003-10-09 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US8420058B2 (en) 1997-06-13 2013-04-16 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20030206870A1 (en) * 1997-06-13 2003-11-06 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US7601336B2 (en) 1997-06-13 2009-10-13 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US7740463B2 (en) 1998-11-25 2010-06-22 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20040096399A1 (en) * 1998-11-25 2004-05-20 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US8142763B2 (en) 1998-11-25 2012-03-27 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining
US20040184993A1 (en) * 1998-11-25 2004-09-23 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition containing HFA 227 and HFA 134a
US20030089369A1 (en) * 1998-11-25 2003-05-15 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20080115782A1 (en) * 1998-11-25 2008-05-22 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (mdi)
US20050142071A1 (en) * 1998-11-25 2005-06-30 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US7347199B1 (en) 1998-11-25 2008-03-25 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20050220717A1 (en) * 1999-06-18 2005-10-06 3M Innovative Properties Company Steroid solution aerosol products with enhanced chemical stability
US20040033201A1 (en) * 1999-06-18 2004-02-19 3M Innovative Properties Company Process for making chemically stable C-17/21 OH 20-ketosteroid aerosol products
US20050034720A1 (en) * 2000-01-07 2005-02-17 Gaetano Brambilla Aerosol inhaler
US20030190289A1 (en) * 2000-05-12 2003-10-09 David Lewis Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US20060083693A1 (en) * 2000-05-22 2006-04-20 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20040101483A1 (en) * 2001-03-30 2004-05-27 Rudi Muller-Walz Medical aerosol formulations
US20110212912A1 (en) * 2001-07-02 2011-09-01 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US7939502B2 (en) 2001-07-02 2011-05-10 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US8168598B2 (en) 2001-07-02 2012-05-01 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US20050163722A1 (en) * 2001-07-02 2005-07-28 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US20100098642A1 (en) * 2001-07-02 2010-04-22 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US7696178B2 (en) 2001-07-02 2010-04-13 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
US20050129621A1 (en) * 2002-03-01 2005-06-16 Chiesi Farmaceutici S.P.A. Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US20090263488A1 (en) * 2002-03-01 2009-10-22 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers containing solutions of beta-2 agonists
US20050154013A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers containing solutions of beta-2 agonists
US20060120966A1 (en) * 2002-10-23 2006-06-08 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation
US8088362B2 (en) 2002-10-23 2012-01-03 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation
US20070020190A1 (en) * 2003-02-27 2007-01-25 Roberta Razzetti Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
US9895327B2 (en) 2003-10-09 2018-02-20 Jagotec Ag Aerosol formulations comprising formoterol fumarate dihydrate
US20070256685A1 (en) * 2003-10-09 2007-11-08 Rudi Mueller-Walz Aerosol Formulations Comprising Formoterol Fumarate Dihydrate
US20070218011A1 (en) * 2003-10-09 2007-09-20 Rudi Mueller-Walz Aerosol Formulation Comprising Formoterol in Suspension
US20070025920A1 (en) * 2004-02-27 2007-02-01 David Lewis Stable Pharmaceutical Solution Formulations for Pressurized Metered Dose Inhalers
US7381402B2 (en) 2004-02-27 2008-06-03 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20050220718A1 (en) * 2004-02-27 2005-10-06 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20070086953A1 (en) * 2004-05-13 2007-04-19 Brian Meakin Medicinal Aerosol Formulation Products With Improved Chemical Stability
US8357352B2 (en) 2004-07-02 2013-01-22 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant
US20060002863A1 (en) * 2004-07-02 2006-01-05 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant
US20090092559A1 (en) * 2006-04-11 2009-04-09 Boehringer Ingelheim Pharma Gbmh Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US8518377B2 (en) * 2006-04-11 2013-08-27 Boehringer Ingelheim Pharma Gbmh Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US10471077B2 (en) 2009-10-16 2019-11-12 Jagotec Ag Medicinal aerosol formulations
US20150297118A1 (en) * 2012-11-15 2015-10-22 Jp Respiratory Technology Ab Device and method for pulmonary function measurement

Also Published As

Publication number Publication date
CA2477881A1 (en) 2003-09-12
CN1638729A (zh) 2005-07-13
KR20040093079A (ko) 2004-11-04
CA2477885C (en) 2010-12-21
CA2477885A1 (en) 2003-09-12
PT1480615E (pt) 2010-06-16
MEP30108A (en) 2010-06-10
MA27175A1 (fr) 2005-01-03
ES2745064T3 (es) 2020-02-27
PT3536344T (pt) 2020-03-26
JP2010215637A (ja) 2010-09-30
EP3494995A2 (en) 2019-06-12
KR100961603B1 (ko) 2010-06-04
EP1480615A1 (en) 2004-12-01
RS76604A (en) 2006-10-27
DE60332321D1 (de) 2010-06-10
RS52387B (en) 2013-02-28
JP2005524664A (ja) 2005-08-18
IL163843A0 (en) 2005-12-18
NO342575B1 (no) 2018-06-18
AU2003210370B2 (en) 2007-08-30
HRP20040752B1 (hr) 2012-10-31
AU2003210370C1 (en) 2008-03-13
PT3384931T (pt) 2019-09-26
NO20043626L (no) 2004-08-31
ATE465712T1 (de) 2010-05-15
NZ535018A (en) 2007-02-23
SI1480615T1 (sl) 2010-07-30
AU2003222753A1 (en) 2003-09-16
CO5611092A2 (es) 2006-02-28
EP2201964A2 (en) 2010-06-30
PE20030827A1 (es) 2003-11-06
EP3494995B1 (en) 2020-02-19
LT3536344T (lt) 2020-04-10
GEP20063986B (en) 2006-12-11
PL209212B1 (pl) 2011-08-31
BR0308274A (pt) 2004-12-28
US20050154013A1 (en) 2005-07-14
CO5611091A2 (es) 2006-02-28
ES2779273T3 (es) 2020-08-14
GEP20063876B (en) 2006-07-10
US8313732B2 (en) 2012-11-20
BRPI0308274B8 (pt) 2021-05-25
LT3494995T (lt) 2020-04-10
CY1122851T1 (el) 2021-05-05
DK3384931T3 (da) 2019-09-16
TW200303752A (en) 2003-09-16
RS76704A (en) 2007-02-05
TNSN04149A1 (en) 2007-03-12
AR038641A1 (es) 2005-01-19
EA007735B1 (ru) 2006-12-29
HUE049426T2 (hu) 2020-09-28
ES2342463T3 (es) 2010-07-07
LT3384931T (lt) 2019-09-25
WO2003074025A3 (en) 2003-12-24
MY143517A (en) 2011-05-31
HRP20040753A2 (en) 2004-12-31
DK3536344T3 (da) 2020-03-16
EP3536344A1 (en) 2019-09-11
DK3494995T3 (da) 2020-03-23
SI3536344T1 (sl) 2020-06-30
PE20030824A1 (es) 2003-11-07
EP1480615B1 (en) 2010-04-28
EA200401007A1 (ru) 2005-04-28
MXPA04008369A (es) 2004-11-26
TWI347197B (en) 2011-08-21
CY1122027T1 (el) 2020-10-14
US20110061651A1 (en) 2011-03-17
EA200401005A1 (ru) 2005-08-25
EP2201964A3 (en) 2013-01-23
NO20043625L (no) 2004-09-29
PL372173A1 (en) 2005-07-11
AU2003222753B2 (en) 2008-04-17
US20090263488A1 (en) 2009-10-22
BR0308275A (pt) 2004-12-28
WO2003074024A1 (en) 2003-09-12
EA008592B1 (ru) 2007-06-29
TNSN04147A1 (en) 2007-03-12
ES2780127T3 (es) 2020-08-24
PL372292A1 (en) 2005-07-11
WO2003074025A2 (en) 2003-09-12
EP3384931B1 (en) 2019-07-24
ME00077B (me) 2010-06-10
HUE048310T2 (hu) 2020-07-28
HUE044926T2 (hu) 2019-11-28
CN1638730A (zh) 2005-07-13
CY1122875T1 (el) 2021-05-05
HK1079425A1 (en) 2006-04-07
JP2005523905A (ja) 2005-08-11
CN100398094C (zh) 2008-07-02
MXPA04008372A (es) 2004-11-26
EP2201964B1 (en) 2018-08-08
BRPI0308274B1 (pt) 2018-10-30
TW200303767A (en) 2003-09-16
CA2477881C (en) 2011-02-01
EP3384931A1 (en) 2018-10-10
IL163844A0 (en) 2005-12-18
CY1111133T1 (el) 2015-06-11
MEP30208A (en) 2010-10-10
EP1480617A2 (en) 2004-12-01
PT3494995T (pt) 2020-03-30
EP3536344B1 (en) 2020-02-19
SI3494995T1 (sl) 2020-08-31
KR20040093080A (ko) 2004-11-04
MY137603A (en) 2009-02-27
AU2003210370A1 (en) 2003-09-16
IL163843A (en) 2011-08-31
DK1480615T3 (da) 2010-07-12
EP3494995A3 (en) 2019-07-24
HRP20040752A2 (en) 2004-12-31
NZ535017A (en) 2007-02-23
SI3384931T1 (sl) 2019-11-29
KR100947409B1 (ko) 2010-03-12
AR038644A1 (es) 2005-01-19

Similar Documents

Publication Publication Date Title
US8313732B2 (en) Formoterol superfine formulation
ZA200406919B (en) Formoterol superfine formulation
US8088362B2 (en) Salmeterol superfine formulation

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHIESI FARMACEUTICI S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAVIES, REBECCA JAINE;GANDERTON, DAVID;LEWIS, DAVID ANDREW;AND OTHERS;REEL/FRAME:016355/0174

Effective date: 20041012

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION